AVBP
ArriVent BioPharma, Inc.
13.51
+0.02 (+0.11%)
52w low 11.36
35.83 high
8.8% of range
Financial Analysis
| (USD) | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Trend |
|---|---|---|---|---|---|---|
| Cash & Equivalents | -- | 163.37M | 150.39M | 74.29M | 45.54M | |
| Receivables | -- | 500.00K | 761.00K | 500.00K | 60.00K | |
| Current Assets | -- | 182.62M | 159.97M | 226.98M | 332.90M | |
| Net PP&E | -- | 139.00K | 291.00K | 154.00K | 13.00K | |
| Total Assets | -- | 182.83M | 163.10M | 274.94M | 333.17M | |
| Current Liabilities | -- | 8.36M | 11.62M | 17.27M | 25.95M | |
| Total Debt | -- | 139.00K | 317.00K | 176.00K | 14.00K | |
| Total Liabilities | -- | 267.94M | 316.29M | 17.29M | 25.95M | |
| Retained Earnings | -- | -88.51M | -157.84M | -238.33M | -404.64M | |
| Shareholders Equity | -- | -85.11M | -153.19M | 257.65M | 307.22M | |
| Working Capital | -- | 174.26M | 148.34M | 209.71M | 306.95M | |
| Shares Outstanding | -- | 31.96M | 31.96M | 33.71M | 42.45M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--